Skip to main content Help with accessibility Skip to main navigation

Sacubitril valsartan

Indication

Treating symptomatic chronic heart failure with reduced ejection fraction (NICE TA388)
NICE TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
For CSR & GP CCGs  only - Must be stabilised by secondary care before transfer to primary care. Initiated by consultant cardiologist
Amber level 0

Brand:

Entresto®

Nice TA:

388

Commissioning responsibility:

CCG

PbR excluded:

No

BNF chapter:
Cardiovascular system

Background

Sacubitril/valsartan is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction, only in people:
• with New York Heart Association (NYHA) class II to IV symptoms and
• with a left ventricular ejection fraction of 35% or less and
• who are already taking a stable dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs).

Recommendation

LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

Decisions of Lancashire local decision making groups

Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
What do the colours mean?

Last Updated: 01 - May - 2016